Literature DB >> 1334687

Pharmacokinetics of mivacurium in normal patients and in those with hepatic or renal failure.

D R Cook1, J A Freeman, A A Lai, Y Kang, R L Stiller, S Aggarwal, J C Harrelson, R M Welch, B Samara.   

Abstract

We have determined the pharmacokinetics and duration of action of a bolus dose of mivacurium (0.15 mg kg-1) during isoflurane and nitrous oxide anaesthesia in nine patients with normal renal and liver function, nine patients undergoing cadaveric kidney transplantation and nine patients undergoing cadaveric liver transplantation. Total plasma concentrations of mivacurium were measured for 2.5 h after administration using a high-pressure liquid chromatographic assay. Plasma concentration vs time data for what were presumed to be the two active mivacurium isomers were analysed by a non-compartmental method based on statistical moments. Neuromuscular block was assessed by measuring the electromyographic evoked response of the adductor pollicis muscle to train-of-four stimulation of the ulnar nerve. The mean time to recovery of 25% neuromuscular transmission, T25, was greater in the patients with liver failure (57.2 min) than in control patients (18.7 min). The volume of distribution at steady rate (Vdss) was comparable in the three groups. Patients with impaired liver function had significantly longer mean residence time and smaller plasma clearance than did patients with renal failure or control patients. There were significant negative correlations between plasma cholinesterase activity and both T25 (r = 0.79) and mean residence time (r = 0.62).

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1334687     DOI: 10.1093/bja/69.6.580

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  14 in total

1.  Peripheral link model as an alternative for pharmacokinetic-pharmacodynamic modeling of drugs having a very short elimination half-life.

Authors:  J Laurin; F Donati; F Nekka; F Varin
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-02       Impact factor: 2.745

Review 2.  Clinical pharmacokinetics of the newer neuromuscular blocking drugs.

Authors:  D P Atherton; J M Hunter
Journal:  Clin Pharmacokinet       Date:  1999-03       Impact factor: 6.447

Review 3.  Newer neuromuscular blocking agents: how do they compare with established agents?

Authors:  H J Sparr; T M Beaufort; T Fuchs-Buder
Journal:  Drugs       Date:  2001       Impact factor: 9.546

4.  Early neuromuscular recovery characteristics following administration of mivacurium plus vecuronium.

Authors:  R G Stout; S J Brull; D Kelly; D G Silverman
Journal:  Can J Anaesth       Date:  1996-04       Impact factor: 5.063

Review 5.  [New muscle relaxants. Update on mivacurium, rocuronium and cis-atracurium].

Authors:  T Fuchs-Buder
Journal:  Anaesthesist       Date:  1997-04       Impact factor: 1.041

Review 6.  The introduction of new drugs into anaesthetic practice: a perspective in pharmaceutical development and regulation.

Authors:  I Gilron
Journal:  Can J Anaesth       Date:  1995-06       Impact factor: 5.063

Review 7.  New muscle relaxants.

Authors:  J E Caldwell
Journal:  West J Med       Date:  1995-01

8.  Succinylcholine.

Authors:  D R Bevan
Journal:  Can J Anaesth       Date:  1994-06       Impact factor: 5.063

Review 9.  Selecting neuromuscular-blocking drugs for elderly patients.

Authors:  Tristan M Cope; Jennifer M Hunter
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 10.  Mivacurium. A review of its pharmacology and therapeutic potential in general anaesthesia.

Authors:  James E Frampton; Donna McTavish
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.